A Japan-based pharmaceutical company that delivers prescription drugs to patients worldwide. Its flagship product is the ...
(NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of TALZENNA ® (talazoparib ...
The FDA previously approved FoundationOne CDx, which uses a tumor tissue sample, and FoundationOne Liquid CDx, which uses a ...
Pfizer (NYSE:PFE) reported positive Phase 3 MagnetisMM-32 results for ELREXFIO in relapsed or refractory multiple myeloma.
Pfizer rolled out the first round of new data since it closed on Xtandi-maker Medivation in September—and the results weren’t good. The blockbuster prostate cancer med fell short in a trial that might ...
Medivation posted second-quarter numbers on Tuesday, and they offer more evidence why Big Pharma and Big Biotech are stumbling over themselves to snap up the company. The company’s flagship drug, ...
On Thursday, Pfizer Inc. (NYSE:PFE) revealed results from the Phase 3 TALAPRO-2 study of Talzenna (talazoparib) in combination with Xtandi (enzalutamide). The trial demonstrated a statistically ...
TALAPRO-2 trial shows Talzenna plus Xtandi improves median OS by 8.8 months in mCRPC patients, reducing death risk by 20.4%. HRR-deficient patients benefit more, with a 38% reduction in death risk and ...
Prostate cancer treatment, Xtandi, received approval in yet another country – Japan. Astellas (ALPMY) and Medivation, Inc. (MDVN) said that Xtandi is now approved for the treatment of patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results